American Journal of Cardiology
Volume 106, Issue 3 , Pages 354-359 , 1 August 2010

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)

  • Terje R. Pedersen, MD, PhD

      Affiliations

    • Center for Preventive Medicine, Oslo University Hospital, and University of Oslo, Norway
    • Corresponding Author InformationCorresponding author: fax: +47-22-60-19-00
    • ,
  • Nilo B. Cater, MD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Ole Faergeman, MD, DMSc

      Affiliations

    • Department of Medicine–Cardiology A, Århus University Hospital, Århus, Denmark
    • ,
  • John J.P. Kastelein, MD, PhD

      Affiliations

    • Academic Hospital Amsterdam, Amsterdam, The Netherlands
    • ,
  • Anders G. Olsson, MD, PhD

      Affiliations

    • Department of Internal Medicine, University Hospital, Linköping, Sweden
    • ,
  • Matti J. Tikkanen, MD, PhD

      Affiliations

    • Medical Clinic, Helsinki University Hospital and Folkhälsan Research Center, Helsinki, Finland
    • ,
  • Ingar Holme, PhD

      Affiliations

    • Center for Preventive Medicine, Oslo University Hospital, and University of Oslo, Norway
    • ,
  • Mogens Lytken Larsen, MD, DMSc

      Affiliations

    • Department of Medicine–Cardiology A, Århus University Hospital, Århus, Denmark
    • ,
  • Christina Lindahl, MD

      Affiliations

    • Pfizer Sweden, Täby, Sweden
    • ,
  • Michael Szarek, PhD

      Affiliations

    • Pfizer, Inc., New York, New York

Received 22 December 2009 ,Revised 15 March 2010 ,Accepted 15 March 2010.

References 

  1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 2007 guidelines for the management of patents with unstable angina/non–ST-elevation myocardial infarction—executive summary. J Am Coll Cardiol. 2007;50:652–726
  2. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halaysyamani LK, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol. 2008;51:210–247
  3. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes (The MIRACL study: a randomized controlled trial). JAMA. 2001;285:1711–1718
  4. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316
  5. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504(published correction appears in N Engl J Med 2006;354:778)
  6. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006;295:2046–2056
  7. Morrissey RP, Diamond GA, Kaul S. Statins in acute coronary syndromes (Do the guideline recommendations match the evidence?). J Am Coll Cardiol. 2009;54:1425–1433
  8. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction (The IDEAL study: a randomized controlled trial). JAMA. 2005;294:2437–2445(published correction appears in JAMA 2005;294:3092)
  9. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. Am J Cardiol. 2004;94:720–724
  10. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study: a novel design for intervention trials (Prospective Randomized Open Blinded End-Point). Blood Press. 1992;1:113–119
  11. Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJP, Olsson AG, et al. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. Eur J Cardiovasc Prev Rehabil. 2009;16:315–320

 The IDEAL study was funded by Pfizer, Inc., New York, New York.

PII: S0002-9149(10)00782-4

doi: 10.1016/j.amjcard.2010.03.033

American Journal of Cardiology
Volume 106, Issue 3 , Pages 354-359 , 1 August 2010

Article Tools

* Image Usage & Resolution